| US 7,541,364 B2 | ||
| Pyridomorphinans, pyridazinomorphinans and use thereof | ||
| Subramaniam Ananthan, Birmingham, Ala. (US); Richard B. Rothman, Baltimore, Md. (US); Edward J. Bilsky, Biddeford, Me. (US); and Frank Porreca, Tucson, Ariz. (US) | ||
| Assigned to Southern Research Institute, Birmingham, Ala. (US) | ||
| Appl. No. 11/718,565 PCT Filed Aug. 27, 2004, PCT No. PCT/US2004/027802 § 371(c)(1), (2), (4) Date Mar. 18, 2008, PCT Pub. No. WO2005/020914, PCT Pub. Date Mar. 10, 2005. |
||
| Claims priority of provisional application 60/497901, filed on Aug. 27, 2003. | ||
| Prior Publication US 2008/0194568 A1, Aug. 14, 2008 | ||
| Int. Cl. A61K 31/4748 (2006.01); C07D 491/12 (2006.01) | ||
| U.S. Cl. 514—279 [546/40; 544/233; 514/248] | 19 Claims |
1. A compound represented by the Formula:
 Wherein R is selected from the group consisting of C1-6 alkyl; C4-6 cycloalkylalkyl; and C3-6 alkenyl;
R′ is H or C1-6 alkyl;
X is H or OH;
Y is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl and aroyl; and
Z is CH or N; provided that when Z is CH and R is C4-6 cycloalkylalkyl or C3-6 alkenyl, then X is H; and
pharmaceutically acceptable salts thereof.
|